ILU Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improved Profitability And Cash GenerationThe recovery in margins and substantial operating and free cash flow provide resources to fund innovation, support customer service, and manage capital needs. Strong cash conversion also improves resilience as Illumina scales clinical and research sequencing.
NovaSeq X Installed-Base ExpansionA growing NovaSeq X installed base can create recurring demand for sequencing reagents and flow cells, strengthening customer retention and revenue visibility. Clinical adoption and higher throughput provide a durable foundation for consumables-led growth.
Raised Growth And Earnings OutlookHigher full-year guidance, alongside Q2 organic growth of 6.5% and strong clinical consumables performance, indicates improving execution. Sustained clinical adoption and instrument demand could support the company’s path toward higher long-term revenue growth.
Bears Say
Persistent Research Consumables WeaknessResearch customers remain an important part of Illumina’s installed base, so prolonged funding caution and lower utilization can suppress recurring consumables revenue. This weakness may offset clinical growth and delay a broad-based recovery.
Moderate Leverage Limits FlexibilityThe balance sheet is serviceable, but leverage reduces flexibility if sequencing demand weakens or investment needs rise. Interest obligations and refinancing requirements could constrain capital allocation during another period of earnings volatility.
Earnings And Cash-Flow Durability RiskThe sharp rebound in profitability follows a volatile multi-year period, making the durability of current earnings less certain. Variable working capital, inventory needs, and uneven cash conversion could reduce the reliability of reported improvement.
Illumina News
ILU FAQ
What was Illumina’s price range in the past 12 months?
Currently, no data Available
What is Illumina’s market cap?
Illumina’s market cap is CHF27.31B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 61 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported CHF1.063 earnings per share for the quarter, beating the consensus estimate of CHF0.995 by CHF0.068.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.1.
How many shares outstanding does Illumina have?
Currently, no data Available
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of CHF1.063 in its last earnings report, beating expectations of CHF0.995. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in CH:ILU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF156.97 (― Upside)
CHF156.97 (― Upside)
Blogger Sentiment
Bullish
CH:ILU Sentiment 80%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth CHF392.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILU Company Deck
ILU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all CH:ILU earnings summariesILU Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
